New hope for liver cancer patients who failed immunotherapy?
NCT ID NCT07310173
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests a new drug called AST-3424 for people with a specific type of advanced liver cancer that has gotten worse after immunotherapy. The trial compares AST-3424 to another standard drug, regorafenib, to see which helps people live longer. About 75 participants will receive either AST-3424 infusions or regorafenib pills, and researchers will track survival rates over 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
RECRUITINGNanjing, Jiangsu, 211102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.